Tzield
Payments companies reported to CMS as associated with Tzield. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Tzield, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Tzield
These are the largest totals companies reported as associated with Tzield. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Jason Baker | New York, NY | Endocrinology, Diabetes & Metabolism | $304,061.46 |
| Teresa Quattrin | Buffalo, NY | $254,837.56 | |
| Kupper Wintergerst | Louisville, KY | Pediatric Endocrinology | $236,462.21 |
| Anita Swamy | Chicago, IL | Pediatric Endocrinology | $235,956.79 |
| Aubrey Molgaard | Ames, IA | Family | $224,411.64 |
| Serge Jabbour | Philadelphia, PA | Endocrinology, Diabetes & Metabolism | $202,877.54 |
| Conan Tu | Massapequa, NY | Internal Medicine | $197,427.28 |
| Natalie Bellini | Mayfield Heights, OH | Family | $196,296.09 |
| Swati Elchuri | Ventura, CA | Pediatric Endocrinology | $188,483.97 |
| Daniel Gozzi | Suitland, MD | Endocrinology, Diabetes & Metabolism | $187,972.04 |
Prescribed Tzield?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.